Abstract
Autologous bone is considered the ‘gold standard’ in bone grafting, but it is not without downfalls. In addition to limited amounts that can be obtained, harvesting autologous bone is associated with up to 30% risk for donor site morbidity.1 Alloplastic bone grafting materials are being developed as an alternative to autologous bone that can be utilized in nearly infinite amounts without the occurrence of a second surgery or donor site morbidity.1 With the potential for release of bioactive agents and customizable erosion, combined with the structural functionality to prevent infiltration of soft tissue, these synthetic materials may offer a suitable substitute to the current ‘gold standard’.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
